Cargando…

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC

Hepatitis C virus infection is a major cause of chronic hepatitis, leading to cirrhosis and hepatocellular carcinoma (HCC). Many studies agree that interferon (IFN)-based antiviral therapy can reduce the risk of HCC recurrence in patients with chronic hepatitis C who have achieved a sustained virolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xiuzhu, Zhan, Mengru, Wang, Liquan, Ding, Yanhua, Niu, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720283/
https://www.ncbi.nlm.nih.gov/pubmed/33299823
http://dx.doi.org/10.2147/JHC.S279657
_version_ 1783619819340300288
author Gao, Xiuzhu
Zhan, Mengru
Wang, Liquan
Ding, Yanhua
Niu, Junqi
author_facet Gao, Xiuzhu
Zhan, Mengru
Wang, Liquan
Ding, Yanhua
Niu, Junqi
author_sort Gao, Xiuzhu
collection PubMed
description Hepatitis C virus infection is a major cause of chronic hepatitis, leading to cirrhosis and hepatocellular carcinoma (HCC). Many studies agree that interferon (IFN)-based antiviral therapy can reduce the risk of HCC recurrence in patients with chronic hepatitis C who have achieved a sustained virological response (SVR). The recent introduction of direct-acting antivirals (DAA) has resulted in excitingly high SVR rates. However, as an IFN-free regimen, DAAs only exert antiviral activity without an immune response. The benefit of DAA-based regimens for HCC recurrence in patients with cirrhosis and following successful curative treatment remains controversial. Additionally, the time span between curative-intent therapy and the DAA regimen is an independent risk factor for HCC recurrence, irrespective of the DAA response. HCC patients who are eligible for potentially curative therapy by liver resection or ablation should defer DAA therapy; however, the accurate timing remains unclear. In this study, we reviewed the timing of DAA initiation after curative treatment and its effect on the recurrence of related HCC.
format Online
Article
Text
id pubmed-7720283
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77202832020-12-08 Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC Gao, Xiuzhu Zhan, Mengru Wang, Liquan Ding, Yanhua Niu, Junqi J Hepatocell Carcinoma Review Hepatitis C virus infection is a major cause of chronic hepatitis, leading to cirrhosis and hepatocellular carcinoma (HCC). Many studies agree that interferon (IFN)-based antiviral therapy can reduce the risk of HCC recurrence in patients with chronic hepatitis C who have achieved a sustained virological response (SVR). The recent introduction of direct-acting antivirals (DAA) has resulted in excitingly high SVR rates. However, as an IFN-free regimen, DAAs only exert antiviral activity without an immune response. The benefit of DAA-based regimens for HCC recurrence in patients with cirrhosis and following successful curative treatment remains controversial. Additionally, the time span between curative-intent therapy and the DAA regimen is an independent risk factor for HCC recurrence, irrespective of the DAA response. HCC patients who are eligible for potentially curative therapy by liver resection or ablation should defer DAA therapy; however, the accurate timing remains unclear. In this study, we reviewed the timing of DAA initiation after curative treatment and its effect on the recurrence of related HCC. Dove 2020-12-01 /pmc/articles/PMC7720283/ /pubmed/33299823 http://dx.doi.org/10.2147/JHC.S279657 Text en © 2020 Gao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Gao, Xiuzhu
Zhan, Mengru
Wang, Liquan
Ding, Yanhua
Niu, Junqi
Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
title Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
title_full Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
title_fullStr Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
title_full_unstemmed Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
title_short Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
title_sort timing of daa initiation after curative treatment and its relationship with the recurrence of hcv-related hcc
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720283/
https://www.ncbi.nlm.nih.gov/pubmed/33299823
http://dx.doi.org/10.2147/JHC.S279657
work_keys_str_mv AT gaoxiuzhu timingofdaainitiationaftercurativetreatmentanditsrelationshipwiththerecurrenceofhcvrelatedhcc
AT zhanmengru timingofdaainitiationaftercurativetreatmentanditsrelationshipwiththerecurrenceofhcvrelatedhcc
AT wangliquan timingofdaainitiationaftercurativetreatmentanditsrelationshipwiththerecurrenceofhcvrelatedhcc
AT dingyanhua timingofdaainitiationaftercurativetreatmentanditsrelationshipwiththerecurrenceofhcvrelatedhcc
AT niujunqi timingofdaainitiationaftercurativetreatmentanditsrelationshipwiththerecurrenceofhcvrelatedhcc